Publications by authors named "Kazuo Oda"

Claim this Profile
R
Radical Scavenging Capacity and In Vitro Cytoprotective Effects of Great Salt Lake-Derived Processed Mineral Water.
Takayuki Mokudai, Seiko Nakagawa, Hiroyasu Kanetaka, Kazuo Oda, Hiroya Abe

Antioxidants (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
Mai Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda, Tsuyoshi Kiyota

Clin Pharmacol Drug Dev· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Daisuke Miyatake, Tomohisa Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda

Clin Pharmacol Drug Dev· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Mai Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda, Tetsuya Nishimura

Eur J Clin Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Mai Shibata, Toshifumi Hatta, Masako Saito, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda

Clin Drug Investig· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Daisuke Miyatake, Tomohisa Shibata, Mai Shibata, Yuichiro Kaneko, Kazuo Oda

Clin Drug Investig· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of metabolites of ASP015K, a novel oral Janus kinase inhibitor, in rats, chimeric mice with humanized liver, and humans.
Naoyuki Nakada, Kazuo Oda

Xenobiotica· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor.
Kazuo Oda, Ying J Cao, Taiji Sawamoto, Naoyuki Nakada, Ogert Fisniku

Xenobiotica· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro/in vivo investigations to examine the gender differences in the pharmacokinetics of novel oral Janus kinase (JAK) inhibitor ASP015K and sulfate metabolite M2 in rats.
Kazuo Oda, Naoyuki Nakada, Yasuhisa Nagasaka

Xenobiotica· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous determination of a novel oral Janus kinase inhibitor ASP015K and its sulfated metabolite in rat plasma using LC-MS/MS.
Kazuo Oda, Katsumi Mera, Yasuhisa Nagasaka, Kazumi Tokoro

Biomed Chromatogr· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure.
Kazuo Oda, Katsuhiro Yamano, Yukio Otsuka

Biopharm Drug Dispos· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506).
Kazuo Oda, Katsuhiro Yamano

Biopharm Drug Dispos· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.
Yasuhisa Nagasaka, Tomokazu Sano, Kazuo Oda, Akio Kawamura, Takashi Usui

Xenobiotica· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506).
Kazuo Oda, Hiroyuki Nemoto, Yasuhisa Nagasaka, Akio Kawamura, Takashi Usui

Biopharm Drug Dispos· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Yasuhisa Nagasaka, Kazuo Oda, Takafumi Iwatsubo, Akio Kawamura, Takashi Usui

Biopharm Drug Dispos· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Nobuaki Shindoh, Masamichi Mori, Yoh Terada, Kazuo Oda, Nobuaki Amino

Int J Oncol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis